GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.
Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...
Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 31.29%, which has investors questioning if this is right time to sell.
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...
Five of the six burn victims airlifted to Arizona are awake and will likely be discharged from the hospital within the next few weeks.
The Marketing Association of Pakistan (MAP) has announced its newly elected office bearers and council members, as per a press release. Muhammad Azfar Ahsan, Founder & Chairman, Nutshell Group, has ...
Closures along Interstate 10 and Interstate 17 will be in place near Tempe and north Phoenix from Feb. 7 to Feb. 10.
IPOBIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST__________THIS IS A RESTRICTED ...
The Express Tribune on MSN11h
Stocks succumb to selling pressure
Heavy selling swept through the Pakistan Stock Exchange (PSX) on Thursday as investor confidence took a beating in the face of concerns about foreign debt repayments and potential changes to the ...
After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...
In a report released on February 5, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with ...
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...